Ipca LaboratoriesNSE:IPCALAB -0.18%86 ROE % is 14.84% as of Mar. 2026, which is 13% above its 10-year median of 13.16. GuruFocus rates NSE:IPCALAB with a GF Score™ of 86/100 and a GF Value™ of ₹1,594.77 (Fairly Valued). The stock has 4 warning signs investors should review. Among 936 Drug Manufacturers companies, Ipca Laboratories ranks better than 78.85% on this metric.
The historical rank and industry rank for Ipca Laboratories's ROE % or its related term are showing as below:
NSE:IPCALAB'
s ROE % Range Over the Past 10 Years
Min: 8.25 Med: 13.16 Max: 27.37
Current: 15.26
During the past 13 years, Ipca Laboratories's highest ROE % was 27.37%. The lowest was 8.25%. And the median was 13.16%.
NSE:IPCALAB's ROE % is ranked better than 78.85% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs NSE:IPCALAB: 15.26
Ipca Laboratories (NSE:IPCALAB) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Ipca Laboratories ROE % Related Terms
Ipca Laboratories ROE % Historical Data
* Premium members only.
The historical data trend for Ipca Laboratories's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipca Laboratories ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's ROE % distribution charts can be found below:
* The bar in red indicates where Ipca Laboratories's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Ipca Laboratories (NSE:IPCALAB) has a ROE % of 14.84% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ipca Laboratories and its competitors. This is 13% above median its historical median of 13.16. Over the past decade, Ipca Laboratories' ROE % has ranged from 8.25 to 27.37. According to the industry distribution chart, Ipca Laboratories ranks #198 out of 936 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is Ipca Laboratories' ROE % too high?
Ipca Laboratories' current ROE % of 14.84% is 13% above median its 10-year median of 13.16. Over the past 10 years, this metric has ranged from a low of 8.25 to a high of 27.37. The Drug Manufacturers industry median ROE % is 5.87. Ipca Laboratories' value of 14.84% is 153% above this industry median. Based on the distribution chart, Ipca Laboratories ranks #198 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ipca Laboratories has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #198 out of 936 companies for ROE %. This places Ipca Laboratories in the top 21% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. Ipca Laboratories' value of 14.84% is 153% above this benchmark. Historically, Ipca Laboratories' own ROE % has ranged from 8.25 to 27.37 over the past decade. While the company's 10-year median is 13.16 vs. the industry median of 5.87, Ipca Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipca Laboratories's current ROE % of 14.84% is 153% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ipca Laboratories and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipca Laboratories's current ROE % is 14.84%, which is 13% above median its own 10-year median of 13.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,594.77, compared to a current price of ₹1,618.30 — trading 1.5% above its estimated fair value. The current ROE % is 14.84%, which is 13% above median its 10-year median of 13.16 and 153% above the Drug Manufacturers industry median of 5.87. Ipca Laboratories' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current ROE % is 14.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued.
The current stock price of ₹1,618.30 is trading 1.5% above its estimated GF Value™ of ₹1,594.77.
GuruFocus considers Ipca Laboratories to be Fairly Valued.
Key valuation signals for NSE:IPCALAB:
ROE %: 14.84% (13% above median its 10-year median of 13.16)
GF Value™: ₹1,594.77 vs. price of ₹1,618.30 (1.5% above fair value)
Industry Position: 153% above the Drug Manufacturers median (#198 of 936)
No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
86GF Score
Get the complete analysis for NSE:IPCALAB
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IPCALAB has been successfully added to your 
